Stoke Therapeutics (STOK) Operating Income Growth (5y) (2023 - 2026)

Stoke Therapeutics (STOK) Operating Income Growth (5y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,912.79 Bn 1,912.72 Bn -
3 Akari Therapeutics 1,045.06 Bn 1,045.06 Bn -
4 BeOne Medicines 470.64 Bn 465.84 Bn 1.35 Bn
5 Vertex Pharmaceuticals 122.91 Bn 115.67 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 70.07 Bn 61.31 Bn 3.31 Bn
7 Belite Bio 62.77 Bn 62.77 Bn -
8 Argenx Se 56.21 Bn 51.02 Bn 1.41 Bn
9 Revolution Medicines 37.60 Bn 37.60 Bn -
10 Stoke Therapeutics 1.87 Bn 1.53 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -25.99%
Dec 31, 2025 -33.32%
Sep 30, 2025 -25.74%
Jun 30, 2025 -15.97%
Mar 31, 2025 62.92%
Dec 31, 2024 -4.29%
Sep 30, 2024 -24.97%
Jun 30, 2024 -28.29%
Mar 31, 2024 -35.02%
Dec 31, 2023 -45.47%
Sep 30, 2023 -52.36%